OBJECTIVE Diabetes mellitus is a syndrome of multiple etiologies. Both type 1 and type 2 diabetes lead to multiple abnormalities of lipid and lipoprotein metabolism. The aim of this investigation was to study the influence of fenofibrate on the blood glucose lowering effect of glibenclamide. MATERIALS AND METHODS Glibenclamide (0.45, 0.23 mg/kg) and fenofibrate (18.1, 9.38 mg/kg) was treated ...

Uridine, a pyrimidine nucleoside, can modulate liver lipid metabolism although its specific acting targets have not been identified. Using mice with fenofibrate-induced fatty liver as a model system, the effects of uridine on liver lipid metabolism are examined. At a daily dosage of 400 mg/kg, fenofibrate treatment causes reduction of liver NAD(+)/NADH ratio, induces hyper-acetylation of peroxi...

BACKGROUND Laser treatment for diabetic retinopathy is often associated with visual field reduction and other ocular side-effects. Our aim was to assess whether long-term lipid-lowering therapy with fenofibrate could reduce the progression of retinopathy and the need for laser treatment in patients with type 2 diabetes mellitus. METHODS The Fenofibrate Intervention and Event Lowering in Diabe...

The standard treatment for aPBC is to combine a fibrate with UDCA. Bezafibrate and fenofibrate are fibrates that elevate serum creatinine levels while decreasing the estimated glomerular filtration rate (eGFR). Pemafibrate selective peroxisome proliferator-activated receptor α modulator, which primarily metabolized by liver. This study assessed effects of switching from pemafibrate in 16 patien...

A wide variety of active pharmaceutical ingredients are released into the environment and pose a threat to aquatic organisms. Drug products using micro- nanoparticle technology can lower these emissions by their increased bioavailability human patients. However, due this enhanced efficacy, nanoscale drug delivery systems potentially display an even higher toxicity, thus also risk non-target Fen...

In this issue of Diabetes, Chen et al. (1) used rodent models of type 1 diabetes and ischemia-induced retinal neovascularization to examine how the lipidlowering drug fenofibrate may prevent progression of diabetic retinopathy. Diabetic retinopathy is the sightthreatening complication of diabetes that causes retinal microvascular dysfunction, which in turn leads to diabetic macular edema (DME),...

Malaria, an infectious disease begins with the introduction of protists into blood circulation and may cause death in severe cases. Development of resistance in Plasmodium parasites is major obstacle and emphasizes the need of novel strategy to combat the prevalent of disease. Fenofibrate, an agonist of peroxisome proliferator-activated receptor alpha (PPAR-α) is well known to treat hypertrigly...

Mixed dyslipidemia is a common lipid disorder characterized by the presence of an atherogenic lipoprotein phenotype due to abnormalities in various atherogenic and anti-atherogenic lipoproteins. Despite the link between the decrease of LDL-cholesterol by statin treatment and the prevention of cardiovascular disease, a high residual risk is observed in statin trials. This residual risk is partly...

Plasma lipoprotein metabolism is influenced by several factors that may act by regulating the expression of proteins involved in lipoprotein metabolism, such as lecithin:cholesterol acyltransferase (LCAT). We determined the influence of several hormones and hypolipidemic drugs on hepatic LCAT gene expression and plasma LCAT activity. Liver LCAT mRNA levels were resistant to regulation by the ho...

OBJECTIVE The metabolic syndrome (MetS) is characterized by insulin resistance and dyslipidemia that may accelerate atherosclerosis. Disturbed apolipoprotein (apo) C-III metabolism may account for dyslipidemia in these subjects. Atorvastatin and fenofibrate decrease plasma apoC-III, but the underlying mechanisms are not fully understood. METHODS AND RESULTS The effects of atorvastatin (40 mg/...